logo
For 3 months, the psychiatric ward was my reality. I lost my freedom, but not hope

For 3 months, the psychiatric ward was my reality. I lost my freedom, but not hope

CBC11-05-2025
This First Person column is the experience of Luke Galati, who lives in Toronto. For more information about CBC's First Person stories, please see the FAQ.
The psychiatric ward is a place no one wants to be.
But it's a place you might need to be at some point if you live with a mental health condition.
There's nothing shameful about admitting that sometimes you need help. In 2023, I spent three months at a hospital in downtown Toronto.
I live with bipolar 1 disorder. The best way to explain what I've gone through when I'm unwell is that I feel the highs more than the lows of others who might have depression.
I've gone through bouts of mania, where I lose touch with reality. I think that people who love me are out to get me. I act irrationally. But inside my mind, my world makes total sense to me. I believe things that I eventually realize aren't true as I come back to my senses.
When I experienced mania, I've done a lot of uncharacteristic and downright odd things. Not just in my mind, but also in the outside world. I bought random furniture online, which is actually still sitting unopened at my home. I even went to the airport to try to take a one-way ticket to Banff. I didn't have any luggage, but at the time, it felt totally rational.
I even walked all the way to the suburbs, 60 kilometres from my home. I thought that there were people on the TV trying to tell me messages. It's like my senses and ability to make sense of the world were temporarily miswired.
At the time of my hospitalization, I had stopped taking my medication and I hadn't slept in days, which is a trigger for me. I recognized that I needed to be hospitalized after a call with my therapist.
It was my longest stay of the four times I've been hospitalized.
I want to demystify what being in a psychiatric ward is like because it was tough for me but it's also possible to have a fulfilling life after it.
And I'm not alone in this experience. According to the Public Health Agency of Canada, each year there are on average 520 mental health-related hospitalizations per 100,000 Canadians aged 15 years or older.
WATCH | People with bipolar disorder answer your questions:
"What happens if you don't take your meds?"
4 years ago
Duration 1:27
By far the hardest place for me to be in the hospital is the intensive care unit (ICU).
This space is small and lacks privacy. You're watched pretty much anywhere that you go. At some hospitals, you have to share a room with someone, which isn't ideal from my experience.
There's nowhere to go in the ICU. There was the bed or the chair in my room or the thin hallway with bright fluorescent hospital lights shining down, with the nursing station behind a wall of glass.
One of the nurses who helped care for me, Lucas Goldman, told me later that the rooms were darker than most places and impersonal by design. It's not a hotel, after all, he said. It's meant to be an unwelcoming place of low stimuli to motivate people to leave rather than stay for long periods of time. Boring by design. Even my phone was taken away until I made progress.
I found the experience tough because I was surrounded by other people who were also struggling. Seeing people of all ages who were in the same boat made me feel like there was something really wrong with me. It made me scared that I'd never snap out of the psychosis that I was going through.
Sometimes it's the little things that you remember most. For me, it's the structure. You get your medication in the morning. The nurses check your blood pressure. Meals come three times per day: breakfast, lunch and dinner on plastic trays. At night, I take my meds. I then do it all over again the next day, every day for three months. That's the point of the psychiatric ward. The structure, meals, meds, sleep and some exercise all helped bring my mania down and kept me steady.
The doctors and nurses are on the other side of a thick piece of glass. It's like being a fish in a tank. It's understood that they need to be able to observe the patients. Pretty much the only time that I wasn't monitored was when I was in the shared washroom.
As I slowly stabilized after the first month, I was moved from the ICU to the 17th floor of the hospital. This was a big step for me and was something that I aspired to because it symbolized progress. More amenities meant more comfort. Having my own room with access to my own washroom and a TV room made a big difference.
In the outside world, I'm a filmmaker and journalist. Naturally, media was a huge outlet for me to get through the hospital days.
Eventually, I was given a radio. This allowed me to listen to music to pass the long days. I found the radio hosts hilarious and they allowed me to feel like I had friends constantly with me, keeping me company.
Being able to catch the news helped me feel connected. It reminded me there's an entire world that's still out there, even if I was stuck inside.
For the first month in the hospital, I wasn't getting much exercise. I was sitting around a lot and I felt restless. I'm someone who's very physically active and loves playing basketball.
So I pretended to play basketball in my room with a yellow bouncy ball. These things sound trivial, but it gave me a sense of play and control in a place where hope can be lost.
I also began walking in my small room, back and forth. I felt like a lion, pacing back and forth in a small cage. I walked from the wall on the east side of the room to the west wall in my room, pacing, getting any movement that I could, all while music played in the background. If you can't run, walk, I told myself.
I read magazines like Sports Illustrated and books about basketball, self-help and the craft of writing. I wrote a book of nearly 400 pages. I expressed myself artistically through writing poetry, thinking of political ideas and reflecting on my life on the outside.
I felt lucky that I had family and friends who would come to see me. This also made a huge difference.
I've had bad experiences with side-effects from medications that I've taken in the past. After finding a medication that finally worked, giving my brain time to cool, it was finally time to leave the hospital three months later. It felt triumphant, knowing that I was leaving the hospital. But I also felt nervous about integrating back into the busy streets of the city that raised me.
I walked through downtown Toronto with a clear blue bag holding all my belongings and took the train back home. Life around me felt like it was moving so fast, like one big blur. I had the goal of just getting home. One step at a time.
Looking back, I realize that being in the hospital isn't the end of my mental health journey. I'm going into my 10th year of volunteering as a basketball coach. I've been focusing on my writing, hoping to one day become a published author.
I hope I won't need to be in a psychiatric ward again. I aspire to live a healthy and happy life, which I believe is possible.
I lost my freedom and sense of control in the psychiatric ward. But I never lost hope and I found my own ways to keep moving forward.
I don't see myself as a victim, but rather someone who went through a tough time.
In late 2024, I made a radio documentary with CBC called Dreaming of Better about the realities that people with bipolar face.
It affirmed the idea that it is possible to manage the condition and live a meaningful life. Turning pain into purpose. It even won an award for reporting on the mental health of young people.
When I meet others who may have a loved one in the psych ward, I encourage them to show patience and give that person grace. Maybe you're going through a trying time with your own mental health. My message is this — don't lose hope.
It was a phase of my life, but it doesn't define me.
I've come to think of my time in the hospital as not the end for me, but rather as a new beginning.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

National Post

time2 hours ago

  • National Post

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Article content Phase 3 data show Bausch + Lomb's LUMIFY Preservative Free eye drops are as safe and effective as the original LUMIFY in reducing ocular redness The multicenter study with 380 participants confirmed that LUMIFY Preservative Free eye drops are non-inferior in efficacy to the original LUMIFY and have a favorable safety profile, offering an effective preservative-free option for sensitive eyes LUMIFY delivers noticeable results in one minute, lasts up to eight hours and is the No. 1 doctor-recommended redness reliever brand; more info at Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology and Therapy has published results from a phase 3 study which assessed the efficacy and safety of LUMIFY Preservative Free redness reliever eye drops compared to LUMIFY redness reliever eye drops for reducing ocular redness. Article content 'Since launching in 2018, LUMIFY has been the No. 1 doctor-recommended redness reliever brand, known for delivering noticeable results in one minute and lasting up to eight hours,' 1 said John Ferris, president, Consumer, Bausch + Lomb. 'This study demonstrates that our new LUMIFY Preservative Free eye drops reduce redness quickly and are just as safe and effective as the original LUMIFY, providing a needed option for patients with eye sensitivities.' Article content In the randomized, active-controlled, multicenter study, 380 participants with ocular redness received either LUMIFY Preservative Free or LUMIFY, administered as a single drop four times daily for four weeks. The primary objective was to demonstrate that LUMIFY Preservative Free is non-inferior to LUMIFY in reducing ocular redness. The primary efficacy endpoint was investigator-assessed ocular redness score at eight timepoints from five-minutes to 240-minutes after drop administration on day one. The secondary objective of the study was to compare the safety of LUMIFY Preservative Free and LUMIFY. Article content The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. A day one analysis of all 11 time points (one minute to 480 minutes post-administration) further supported these findings; and additional secondary efficacy endpoint data from one minute, 360 minutes and 480 minutes post-administration demonstrated that LUMIFY Preservative Free performs similarly to LUMIFY. The overall safety profile of LUMIFY Preservative Free was favorable and comparable to LUMIFY, and the occurrence of ocular treatment-emergent adverse events was similar in both treatment groups. In this clinical trial, LUMIFY Preservative Free demonstrated to have a low incidence of side effects, like rebound redness and loss of efficacy over time, when used as directed. Article content 'The results show that LUMIFY Preservative Free is a well-tolerated alternative option for consumers with ocular redness who have sensitivities to preservatives or are at increased risk of ocular surface disease,' said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, TN. Article content About the LUMIFY Brand Article content The LUMIFY brand began in 2018 with the U.S. launch of LUMIFY redness reliever eye drops. Before LUMIFY, redness relievers relied on the same ingredients for decades and were associated with well-known side effects. LUMIFY and LUMIFY Preservative Free are the only over-the-counter redness relievers formulated with low-dose brimonidine tartrate 0.025% that selectively target eye redness and offer excellent results with a lower risk of rebound redness and loss of efficacy when used as directed. In 2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS™, a line of specialty eye care products specifically developed for the sensitive area around the eyes. In June 2025, Bausch + Lomb launched LUMIFY Preservative Free eye drops in the U.S. For more information on the LUMIFY brand, visit Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit Article content Facebook Article content , Article content Instagram Article content , Article content LinkedIn Article content , Article content X Article content and Article content YouTube Article content . Article content References Article content ©2025 Bausch + Lomb. Article content Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Kristy Marks Article content Article content Article content

Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL
Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL

Globe and Mail

time2 hours ago

  • Globe and Mail

Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL

(LLY)), Loxo Oncology Inc ((LOXO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly and Company, in collaboration with Loxo Oncology Inc., is conducting a Phase 3 study titled 'A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)'. The study aims to evaluate the efficacy and safety of the experimental drug Pirtobrutinib compared to the standard treatment of Bendamustine plus Rituximab in patients who have not received prior treatment for CLL/SLL. The study tests two interventions: Pirtobrutinib, an oral medication, and a combination of Bendamustine and Rituximab, administered intravenously. Pirtobrutinib is being evaluated for its potential to offer a more effective and safer treatment option. This interventional study is randomized with a parallel assignment model. Participants are divided equally into two groups, with no masking involved. The primary purpose is treatment, allowing crossover for patients with disease progression. The study began on September 23, 2021, with an active but not recruiting status. The last update was submitted on July 22, 2025, indicating ongoing progress. These dates are crucial for tracking the study's development and anticipated results. The outcome of this study could significantly impact Eli Lilly's and Loxo Oncology's stock performance by potentially introducing a new treatment option in the CLL/SLL market. This could influence investor sentiment positively, especially if Pirtobrutinib proves to be a superior treatment. Competitors in the oncology space will be closely monitoring these developments. The study remains active, with further details available on the ClinicalTrials portal.

Happy days for fundraising campaign in New Tecumseth
Happy days for fundraising campaign in New Tecumseth

CTV News

time3 hours ago

  • CTV News

Happy days for fundraising campaign in New Tecumseth

Alliston and Angus McDonald's McHappy Day raised $12,500 for the Stevenson Memorial Hospital Foundation (SMHF). In addition, SMHF received an extra $14,000 during its Because of YOU relaunch event, further strengthening its partnership and commitment to hospital redevelopment efforts. Together, this funding brings the total contributions from MacKinnon Restaurants, that owns McDonald's in both Alliston and Angus, to an impressive $200,000 to the Stevenson Memorial Hospital Foundation. 'We're incredibly proud to be part of a community that values and supports our local hospital. Every dollar raised during events like McHappy Day makes a real difference—it helps us provide the best possible care for our family, neighbours, and loved ones,' said Rory MacKinnon, owner/operator of McDonald's in Alliston and Angus. The Because of You campaign is an effort to raise funds from the community to help build a future of Stevenson Memorial Hospital. This project will triple the size of the hospital, provide expanded emergency care and advanced diagnostic imaging, including Stevenson's first MRI suite. Community funds will also be put toward modern inpatient facilities, and specialized surgical services, all designed to meet the evolving healthcare needs of the growing community. 'We are deeply grateful to McDonald's in Alliston and Angus for their incredible generosity and unwavering support during McHappy Day. 'Their contributions play a crucial role in our overall efforts to advance the construction of Stevenson's new facility, which will significantly enhance healthcare services for our community,' said Frank Cerisano, CEO for SMHF. 'This support is significant as it helps us progress towards our $80 million Because of YOU campaign goal, helping to ensure that every patient continues to receive the quality care they deserve today and for generations to come.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store